6th May 2020 Content supplied by: ARTES Biotechnology
ARTES Adapts Malaria & Lyme Disease Vaccine Candidates for SARS-CoV-2
ARTES Biotechnology, the German-based biotech company, specializing in process development for recombinant vaccines, has entered into the development of SARS-CoV-2 vaccine candidates based on its virus-like particle (VLP) based platform technologies METAVAX® and SplitCore.
METAVAX® is the company´s platform for the development of vaccines built on enveloped virus-like particle nanostructures (eVLPs) based on the duck Hepatitis B small surface antigen. SplitCore is the technology where capsid virus-like particles (cVLPs) are applied as antigen presentation vehicles without the involvement of host lipid membrane structures.
The development approach of ARTES is designed to present domains of the spike protein of SARS-CoV-2 – with or without an antigen derived from the virus´ nucleocapsid protein – on the surface of eVLPs (METAVAX) and cVLPs (SplitCore).
Virus-like particles are highly organized protein structures that mimic the conformation of authentic native viruses without being infectious. They consist of one or more structural proteins that can self-assemble to mimic the structure of real viruses and to present foreign epitopes or complete antigens on their surface. Because of lacking a viral genome, recombinant VLPs are superior to native viruses while at the same time maintaining the same potential to trigger a strong immune response.
In September 2019, ARTES and Australian Burnett Institute published data on the efficient production of malaria vaccine candidates using virus-like particles (eVLP) produced with ARTES’ METAVAX platform presenting malaria transmission-stage antigens, which were capable of inducing transmission-blocking antibodies (journals.plos.org/plosone/article?id=10.1371/journal.pone.0221733).
For SplitCore platform, borrelia antigen-presenting cVLP was developed by a research team of the University of Freiburg and resulted in the induction of neutralizing antibodies against Lyme disease.
In a similar approach, SARS-CoV-2 antigens known to induce neutralizing antibodies will be presented by METAVAX® and SplitCore VLPs.
ARTES Biotechnology has specific expertise in vaccine process development from microbial expression systems with several products out-licensed. The company offers two versatile and proven virus-like particle (VLP) platform technologies for the development of vaccine candidates. The resulting virus-like particles from bacterial and yeast cell lines are applicable as highly immunogenic subunit vaccines in human and animal health.
Date Published: 6th May 2020
Source article link: View
Intense Engineering Releases High-Speed COVID-19
Hands-Free LabElite Products Aid COVID-19